Interpretation and use of natriuretic peptides in non-congestive heart failure settings
- PMID: 20191004
- PMCID: PMC2824858
- DOI: 10.3349/ymj.2010.51.2.151
Interpretation and use of natriuretic peptides in non-congestive heart failure settings
Abstract
Natriuretic peptides (NPs) have been found to be useful markers in differentiating acute dyspneic patients presenting to the emergency department (ED) and emerged as potent prognostic markers for patients with congestive heart failure (CHF). The best-established and widely used clinical application of BNP and NT-proBNP testing is for the emergent diagnosis of CHF in patients presenting with acute dyspnea. Nevertheless, elevated NPs levels can be found in many circumstances involving left ventricular (LV) dysfunction or hypertrophy; right ventricular (RV) dysfunction secondary to pulmonary diseases; cardiac inflammatory or infectious diseases; endocrinology diseases and high output status without decreased LV ejection fraction. Even in the absence of significant clinical evidence of volume overload or LV dysfunction, markedly elevated NP levels can be found in patients with multiple comorbidities with a certain degree of prognostic value. Potential clinical applications of NPs are expanded accompanied by emerging reports regarding screening the presence of secondary cardiac dysfunction; monitoring the therapeutic responses, risk stratifications and providing prognostic values in many settings. Clinicians need to have expanded knowledge regarding the interpretation of elevated NPs levels and potential clinical applications of NPs. Clinicians should recognize that currently the only reasonable application for routine practice is limited to differentiation of acute dyspnea, rule-out-diagnostic-tests, monitoring of therapeutic responses and prognosis of acute or decompensated CHF. The rationales as well the potential applications of NPs in these settings are discussed in this review article.
Keywords: Natriuretic peptides; acute coronary syndrome; carbon monoxide intoxication; cardiac dysrhythmia; cirrhosis of liver; hyperthyroidism; pulmonary embolism; pulmonary hypertension; renal failure; sepsis; stroke.
Conflict of interest statement
The authors have no financial conflicts of interest.
Figures
Similar articles
-
Diagnostic and prognostic impact of brain natriuretic peptide in cardiac and noncardiac diseases.Heart Lung. 2008 Jul-Aug;37(4):275-85. doi: 10.1016/j.hrtlng.2007.05.010. Heart Lung. 2008. PMID: 18620103
-
Advances in congestive heart failure management in the intensive care unit: B-type natriuretic peptides in evaluation of acute heart failure.Crit Care Med. 2008 Jan;36(1 Suppl):S17-27. doi: 10.1097/01.CCM.0000296266.74913.85. Crit Care Med. 2008. PMID: 18158473 Review.
-
Interpretation of B-type natriuretic peptide in cardiac disease and other comorbid conditions.Heart Fail Rev. 2007 Mar;12(1):23-36. doi: 10.1007/s10741-007-9002-9. Epub 2007 Mar 8. Heart Fail Rev. 2007. PMID: 17345160 Review.
-
[Natriuretic peptides--new diagnostic markers in heart disease].Herz. 2004 Sep;29(6):609-17. doi: 10.1007/s00059-004-2619-8. Herz. 2004. PMID: 15912436 Review. German.
-
B-type natriuretic peptides. A diagnostic breakthrough in heart failure.Minerva Cardioangiol. 2003 Apr;51(2):121-9. Minerva Cardioangiol. 2003. PMID: 12783068 Review.
Cited by
-
Natriuretic peptides, extracellular volume, and subclinical cardiovascular changes in chronic kidney disease stages 1-3: a pilot study.J Investig Med. 2022 Jul 19:jim-2022-002467. doi: 10.1136/jim-2022-002467. Online ahead of print. J Investig Med. 2022. PMID: 35853670 Free PMC article.
-
Early-pregnancy N-terminal pro-brain natriuretic peptide level is inversely associated with hypertensive disorders of pregnancy diagnosed after 35 weeks of gestation.Sci Rep. 2024 May 28;14(1):12225. doi: 10.1038/s41598-024-63206-5. Sci Rep. 2024. PMID: 38806648 Free PMC article.
-
Predictors of Peak Troponin Level in Acute Coronary Syndromes: Prior Aspirin Use and SYNTAX Score.Int J Angiol. 2016 Mar;25(1):54-63. doi: 10.1055/s-0035-1547396. Epub 2015 Mar 23. Int J Angiol. 2016. PMID: 26900312 Free PMC article.
-
A review on B-type natriuretic peptide monitoring: assays and biosensors.Heart Fail Rev. 2016 Sep;21(5):567-78. doi: 10.1007/s10741-016-9544-9. Heart Fail Rev. 2016. PMID: 26979601 Free PMC article. Review.
-
Circulating biomarker correlates of left atrial size and myocardial extracellular volume fraction among persons living with and without HIV.BMC Cardiovasc Disord. 2022 Sep 3;22(1):393. doi: 10.1186/s12872-022-02835-y. BMC Cardiovasc Disord. 2022. PMID: 36057773 Free PMC article.
References
-
- Swedberg K, Cleland J, Dargie H, Drexler H, Follath F, Komajda M, et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J. 2005;26:1115–1140. - PubMed
-
- Januzzi JL, van Kimmenade R, Lainchbury J, Bayes-Genis A, Ordonez-Llanos J, Santalo-Bel M, et al. NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the International Collaborative of NT-proBNP Study. Eur Heart J. 2006;27:330–337. - PubMed
-
- Kisch B. Electron microscopy of the atrium of the heart. I. Guinea pig. Exp Med Surg. 1956;14:99–112. - PubMed
-
- De Bold AJ. Heart atria granularity effects of changes in water-electrolyte balance. Proc Soc Exp Biol Med. 1979;161:508–511. - PubMed
-
- Iwanaga Y, Nishi I, Furuichi S, Noguchi T, Sase K, Kihara Y, et al. B-type natriuretic peptide strongly reflects diastolic wall stress in patients with chronic heart failure: comparison between systolic and diastolic heart failure. J Am Coll Cardiol. 2006;47:742–748. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous